Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don’t know about that. With possible GREENLIGHT from FDA in the next few weeks I’d assume you have to be a complete moron to continue to short. The shorting went from a normal 5-700k to over 2 million to now over 3 million. This is when share price declined from .40 down to low mid .20. At this point. You won shorters. Cash out and cover. This is not going lower. I’d like to see $1 by Thanksgiving.
Oh snap!!!!!! So in all seriousness that is the highest I’ve ever seen. Someone is really betting against Leo. Let’s get some good news and start this trial.
Trial start always bumps share price. And I’d say an interim readout could really increase the price if good and media grabs on. We are going to move into Oct Nov which brings many of the US states indoors and flu season. So it could get interesting again
Good post. Thx
“Lastly, the manufacturing of Brilacidin intravenous (IV) drug product is expected to produce an amount in excess of what is estimated to be required for the Company’s planned Phase 2 clinical trial, allowing for extra IV drug product to support potential additional COVID-19 clinical testing.”
Hint hint friends.
Trial results will open all eyes. Get in now at .24 or in December join in at much higher. Hopefully we see the MCs of other Cov19 drug companies. 16 billion maybe? Lol. Come on Dud.
You’re welcome. And thank you!
Agree. I read it as the process will begin full steam ahead in early Sept.
I think we will have the drug. We have the money and the additional funding if needed. The FDA needs to see all of that and I hope for EUA and also grant money to run the trials and also manufacture even more B...quickly...if early trial data is promising.
“Interactions with the Food and Drug Administration, through its Coronavirus Treatment Acceleration Program, are anticipated to begin early September, along with the selection of a Contract Research Organization to implement the Brilacidin for COVID-19 clinical trial.”
Agree. The trial will be so much fun to watch!
Comparison SI’s:
Remdesivir SI 129.87
Cloroquine SI 88.5
Favipiravir SI 6.46
Penciclovir SI 4.17
Ribavirin SI 3.65
We witnessed Remdesivir’s underwhelming interim results on Friday.
Brilacidin is greater than 300
It will be fun to watch this trial!!!
Farrell posted a while ago with links. Don’t have it on hand
SI
Remdesivir SI 129.87
Cloroquine SI 88.5
Favipiravir SI 6.46
Penciclovir SI 4.17
Ribavirin SI 3.65
Brilacidin. Greater than 300
NEWS! Awesome SI. Trials to begin
COVID-19 Drug Candidate Brilacidin Achieves a Selectivity Index Among the Highest Reported, Exhibiting Potent Anti-SARS-CoV-2 Activity at Low Concentrations; Clinical Trial Forthcoming
Preliminary data shows Brilacidin’s Selectivity Index (SI), a ratio that compares a drug’s cytotoxicity and antiviral activity, to be greater than 300 in a human lung epithelial cell line
Brilacidin’s SI is higher than the SIs of a vast majority of other antiviral drugs being evaluated as COVID-19 treatments; a high SI means a drug is more likely to be safe and effective in the clinic
WAKEFIELD, MA – August 24, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, reports today receiving additional data from a U.S. Regional Biocontainment Laboratory (RBL) based on ongoing in vitro testing supporting Brilacidin as a potential treatment for SARS-CoV-2, the novel coronavirus responsible for COVID-19.
“The latest Brilacidin in vitro efficacy results against SARS-CoV-2 are outstanding,” noted Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “Selectivity Index is arguably the most important measure to compare the antiviral efficacy between experimental drugs and this new data suggests Brilacidin is in an elite group of anti-coronavirus candidates. For a point of reference, a SI greater than 100 is considered exceptional. Unlike thousands of other compounds and drugs under consideration as COVID-19 treatments, Brilacidin is demonstrating remarkably consistent and potent anti-SARS-CoV-2 activity in RBL testing, suggesting Brilacidin has tremendous potential as a COVID-19 treatment. We are actively planning to get Brilacidin into human testing as fast as possible, following necessary approvals and set-up procedures.”
In a new experiment at the RBL in a human lung epithelial cell line, Brilacidin, when directly incubated with the live (or wild type) virus, was shown to inhibit the virus by 50 percent (the IC50 value) at a mid-nanomolar concentration, while remaining non-cytotoxic to cells at high micromolar concentrations—establishing a SI for Brilacidin greater than 300 in this lung cell line. Additionally, this new testing in the human lung cell line showed Brilacidin’s IC90 value to be in the low micromolar range.
Based on public information (https://ghddi-ailab.github.io/Targeting2019-nCoV/preclinical/), a vast majority of other drugs being evaluated as COVID-19 treatments, including repurposed drugs, have SIs that are much lower than that achieved by Brilacidin. Moreover, according to a recent screening of 5,632 compounds (https://www.researchsquare.com/article/rs-23951/v1), including 3,488 compounds that have undergone clinical stage testing across 600 indications, only 19 compounds were identified as having an IC50 in the nanomolar (<1µM) range, as Brilacidin achieved, when tested against SARS-CoV-2.
Brilacidin has now exhibited robust in vitro anti-SARS-CoV-2 efficacy at low concentrations, well below already established clinically-achievable concentrations based on pharmacokinetics observed in the Company’s Phase 2b clinical trial of Brilacidin in Acute Bacterial Skin and Skin Structure Infections.
In other news, the Company is preparing to expedite planned clinical testing of Brilacidin for COVID-19, including identification of clinical trial sites. Interactions with the Food and Drug Administration, through its Coronavirus Treatment Acceleration Program, are anticipated to begin early September, along with the selection of a Contract Research Organization to implement the Brilacidin for COVID-19 clinical trial. Lastly, the manufacturing of Brilacidin intravenous (IV) drug product is expected to produce an amount in excess of what is estimated to be required for the Company’s planned Phase 2 clinical trial, allowing for extra IV drug product to support potential additional COVID-19 clinical testing.
Lol! Or back to his first promotion of hydroxy and zpack
I’d like to see the peer review in parallel with a grant for pan coronavirus research. Let’s increase the value of B for far more than just Covid-19
President Trump plans to hold a news conference Sunday evening regarding a potential major therapeutic "breakthrough" for treating the coronavirus.
The president will announce the development at 6 p.m., accompanied by Health and Human Services Secretary Alex Azar and Dr. Stephen Hahn, head of the Food and Drug Administration, White House press secretary Kayleigh McEnany posted on Twitter late Saturday.
Earlier in the day, the president suggested someone at the FDA was purposefully trying to delay clinical trials for therapeutics and vaccines for political purposes.
Let’s GO!!! Lol. I bet it’s about Hydro again though.
Added today as well. I just hit the ask as I’m confident the next news into sept and oct will be explosive.
Good luck to both of us. It’s time for B to shine in this pandemic.
What is it? Was at 2 million ... up from 700k last report. July 31
Who posted current treatment SI scores?
If our SI score is double digits better than current....then what?
Right. That is a lot in 15 days for this ticker. 700k to over 2 million.
This company should gain traction with final data to be peer reviewed in a few weeks. If the SI index shows better than approved drugs we should gain national attention. Hold tight folks.
I do get frustrated and after reading this board I also get a little sideways.....but after the dust settles I realize just how calm and collective Leo is. He just allows the drug to do its work in the process. I think the extra data we get from paying GMU will be helpful for fda and guidance.
I think there is a major difference from a drug dosing 400 plus in clinical trials and a drug approved for the past 30 years. We will see a phase 2 imo. Small and quick trial is my guess. But, I’m wrong often.
No. Aspire was a great partner. Best financing we’ve ever had. Leo controls when and how much.
Correct. Plus it’s up to Leo to call the days. Rally back to 4 please.
6 million in bank
30 million available.
They have cash buddy. Up to 30million
30 million. Leo controls the sale. .10 the stop. Okay. Big news
Leo said. With each test results he is provided with....it brings the company closer to human trials. We have not had one negative test.
It takes time.
Innovation Pharmaceuticals and U.S. Regional Biocontainment Laboratory Nearing Completion of Brilacidin Anti-SARS-CoV-2 (COVID-19) In Vitro Testing
Brilacidin is showing consistent and robust antiviral activity across the viral lifecycle in human lung and Vero cells; potential as a treatment for preventing infection with COVID-19, as well as for treatment of patients once infected
Article to be submitted for peer-review publication in September, with pre-print made available
WAKEFIELD, MA – August 4, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, reports today receiving an update from a U.S. Regional Biocontainment Laboratory (RBL) based on ongoing in vitro testing supporting Brilacidin as a treatment for SARS-CoV-2, the novel coronavirus responsible for COVID-19.
A new experiment in a human lung epithelial cell line with the live (or wild type) virus showed that Brilacidin inhibited SARS-CoV-2 when administered post-infection. These results complement earlier RBL experiments in the same lung cell line that showed Brilacidin, when directly incubated with the live virus, exhibited potent inhibition. As Brilacidin is showing consistent and robust anti-SARS-CoV-2 activity across the viral lifecycle, the Company believes the drug could be used as a treatment for preventing infection with COVID-19, as well as for treatment of patients once infected.
At the RBL, ongoing direct inhibition experiments are being conducted with the live virus, including experiments to determine the Selectivity Index—a ratio that compares a drug’s cytotoxicity and antiviral activity—of Brilacidin in human lung cells and also in Vero cells. New in vitro neutralization experiments (with a pseudotyped virus) and binding experiments (using isolated SARS-CoV-2 Spike protein) are helping to further elucidate Brilacidin’s antiviral mechanisms against SARS-CoV-2. The richness of the growing RBL data is informing our planned Phase 2 clinical trial of Brilacidin for COVID-19. Upon completion of in vitro testing at the RBL, an academic paper is anticipated to be submitted in September for peer-review publication, with a pre-print to be made available at that time.
NEWS. TESTING ALMOST DONE. NEW DATA SUGGESTS BRILACIDIN CAN PREVENT THE VIRUS
Great write up on Brilacidin.
They have a set amount of shares. This too shall pass. And then with Trials and Grant news in the fall this will explode - I promise you that.
Could be. That’s my thought.
I just pray B gets a shot on goal which appears it will and then we have in states manufacturing ready to roll once approved.
A lot of brush to burn still with Covid.
How? You ask.
Manufacturing complete and tested
FDA go ahead for phase 2
Grant news
Positive SI data or additional data
UPS trial start - 1 million milestone
The list goes on.......
The .65 is just a step and with MFO getting out of the way there will be very little resistance. IMO
Stay long and strong. We rise sharp soon.
Wow! Reverse Split Talk. George Evans talk, MFO talk. Defines Desperation.
Crazy times ahead when they lose this battle
Yup. It could anytime! But!!! IMO the big mover....like $$$$$$’s will be when B enters the hospital scene and performs well! Based on the Covid bubble and other stock market caps....I’d assume multi billions market cap if it plays out
I’d say...we look forward to Brilacidin being delivered and ready for trials. Then FDA good graces...then trial for Covid begins.
Those next steps will move this share price.
We can have more data in the mean time....possible grant news......(IMO this big news happens if B is delivering good results in hospitals during phase 2 trial)....possible partnerships....IBD updates, OM updates etc.
Good news and share price increases to come. IMO.